51/120
2.1 / 5 stars
All 120 Win/Lose results shown below
CYRX Roast Me summary
Cryoport, Inc. (CYRX). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinCYRX / S&P 89.61% / 15.20% |
LoseCYRX / S&P 12.14% / 15.00% |
LoseCYRX / S&P -164.54% / 50.40% |
| 2026-Q11/3 |
LoseCYRX / S&P -13.75% / -4.33% |
WinCYRX / S&P 13.97% / 11.30% |
LoseCYRX / S&P CYRX unavailable / 27.70% |
| 2025-Q41/3 |
LoseCYRX / S&P 1.27% / 2.65% |
WinCYRX / S&P 12.38% / 9.00% |
LoseCYRX / S&P CYRX unavailable / 13.40% |
| 2025-Q32/3 |
WinCYRX / S&P 27.08% / 8.12% |
WinCYRX / S&P 59.45% / 4.61% |
LoseCYRX / S&P CYRX unavailable / 13.45% |
| 2025-Q22/3 |
WinCYRX / S&P 22.70% / 10.94% |
WinCYRX / S&P 32.14% / 4.83% |
LoseCYRX / S&P CYRX unavailable / 10.63% |
| 2025-Q11/3 |
LoseCYRX / S&P -21.85% / -4.27% |
WinCYRX / S&P 12.14% / 4.98% |
LoseCYRX / S&P CYRX unavailable / 10.57% |
| 2024-Q40/3 |
LoseCYRX / S&P -4.07% / 2.41% |
LoseCYRX / S&P -7.05% / 5.25% |
LoseCYRX / S&P CYRX unavailable / 6.15% |
| 2024-Q31/3 |
WinCYRX / S&P 17.37% / 5.89% |
LoseCYRX / S&P -54.31% / 5.89% |
LoseCYRX / S&P CYRX unavailable / 6.11% |
| 2024-Q20/3 |
LoseCYRX / S&P -60.96% / 4.28% |
LoseCYRX / S&P -47.72% / 5.38% |
LoseCYRX / S&P CYRX unavailable / 5.12% |
| 2024-Q11/3 |
WinCYRX / S&P 14.27% / 10.56% |
LoseCYRX / S&P -42.24% / 5.71% |
LoseCYRX / S&P CYRX unavailable / 5.59% |
| 2023-Q41/3 |
WinCYRX / S&P 12.98% / 11.69% |
LoseCYRX / S&P -28.92% / 6.81% |
LoseCYRX / S&P CYRX unavailable / 7.78% |
| 2023-Q30/3 |
LoseCYRX / S&P -20.52% / -3.27% |
LoseCYRX / S&P 1.28% / 7.52% |
LoseCYRX / S&P CYRX unavailable / -5.03% |
| 2023-Q20/3 |
LoseCYRX / S&P -28.13% / 8.74% |
LoseCYRX / S&P 4.82% / 9.50% |
LoseCYRX / S&P CYRX unavailable / -8.57% |
| 2023-Q12/3 |
WinCYRX / S&P 38.33% / 7.50% |
WinCYRX / S&P 11.81% / 10.77% |
LoseCYRX / S&P CYRX unavailable / -15.69% |
| 2022-Q40/3 |
LoseCYRX / S&P -28.78% / 7.56% |
LoseCYRX / S&P 6.59% / 11.88% |
LoseCYRX / S&P CYRX unavailable / -17.99% |
| 2022-Q30/3 |
LoseCYRX / S&P -21.37% / -4.88% |
LoseCYRX / S&P 8.78% / 13.47% |
LoseCYRX / S&P CYRX unavailable / -1.41% |
| 2022-Q22/3 |
WinCYRX / S&P -11.26% / -16.10% |
WinCYRX / S&P 35.84% / 13.71% |
LoseCYRX / S&P CYRX unavailable / 11.04% |
| 2022-Q11/3 |
LoseCYRX / S&P -41.00% / -4.60% |
WinCYRX / S&P 81.35% / 15.97% |
LoseCYRX / S&P CYRX unavailable / 42.23% |
| 2021-Q41/3 |
LoseCYRX / S&P -11.04% / 11.03% |
WinCYRX / S&P 182.87% / 15.00% |
LoseCYRX / S&P CYRX unavailable / 96.40% |
| 2021-Q32/3 |
WinCYRX / S&P 5.40% / 0.58% |
WinCYRX / S&P 442.05% / 10.77% |
LoseCYRX / S&P CYRX unavailable / 69.42% |
| 2021-Q22/3 |
WinCYRX / S&P 21.32% / 8.55% |
WinCYRX / S&P 344.89% / 6.58% |
LoseCYRX / S&P CYRX unavailable / 51.81% |
| 2021-Q12/3 |
WinCYRX / S&P 18.53% / 6.17% |
WinCYRX / S&P 229.72% / -1.06% |
LoseCYRX / S&P CYRX unavailable / 7.39% |
| 2020-Q41/3 |
LoseCYRX / S&P -7.43% / 12.15% |
WinCYRX / S&P 131.85% / -3.72% |
LoseCYRX / S&P CYRX unavailable / -33.42% |
| 2020-Q32/3 |
WinCYRX / S&P 56.69% / 8.93% |
WinCYRX / S&P 30.23% / -2.04% |
LoseCYRX / S&P CYRX unavailable / -27.10% |
| 2020-Q22/3 |
WinCYRX / S&P 77.21% / 20.54% |
WinCYRX / S&P 45.59% / -0.46% |
LoseCYRX / S&P CYRX unavailable / -27.11% |
| 2020-Q12/3 |
WinCYRX / S&P 3.71% / -19.60% |
WinCYRX / S&P 66.53% / 3.47% |
LoseCYRX / S&P CYRX unavailable / -14.75% |
| 2019-Q41/3 |
LoseCYRX / S&P 0.61% / 9.07% |
WinCYRX / S&P 72.94% / 5.36% |
LoseCYRX / S&P CYRX unavailable / 2.99% |
| 2019-Q31/3 |
LoseCYRX / S&P -10.70% / 1.70% |
WinCYRX / S&P 76.10% / 5.02% |
LoseCYRX / S&P CYRX unavailable / 0.21% |
| 2019-Q22/3 |
WinCYRX / S&P 41.80% / 4.30% |
WinCYRX / S&P 74.24% / 6.64% |
LoseCYRX / S&P CYRX unavailable / 8.65% |
| 2019-Q12/3 |
WinCYRX / S&P 17.14% / 13.65% |
WinCYRX / S&P 67.78% / 8.12% |
LoseCYRX / S&P CYRX unavailable / 14.29% |
| 2018-Q41/3 |
LoseCYRX / S&P -13.90% / -13.52% |
WinCYRX / S&P 64.18% / 9.05% |
LoseCYRX / S&P CYRX unavailable / 18.23% |
| 2018-Q31/3 |
LoseCYRX / S&P -18.82% / 7.71% |
WinCYRX / S&P 58.89% / 10.21% |
LoseCYRX / S&P CYRX unavailable / 19.06% |
| 2018-Q22/3 |
WinCYRX / S&P 83.49% / 3.43% |
WinCYRX / S&P 52.26% / 9.03% |
LoseCYRX / S&P CYRX unavailable / 14.46% |
| 2018-Q12/3 |
WinCYRX / S&P 0.12% / -0.76% |
WinCYRX / S&P 50.14% / 7.68% |
LoseCYRX / S&P CYRX unavailable / 12.46% |
| 2017-Q41/3 |
LoseCYRX / S&P -12.79% / 6.64% |
WinCYRX / S&P 55.68% / 7.03% |
LoseCYRX / S&P CYRX unavailable / 13.82% |
| 2017-Q32/3 |
WinCYRX / S&P 100.20% / 4.48% |
WinCYRX / S&P 57.21% / 5.68% |
LoseCYRX / S&P CYRX unavailable / 17.57% |
| 2017-Q22/3 |
WinCYRX / S&P 108.47% / 3.09% |
WinCYRX / S&P 54.43% / 4.83% |
LoseCYRX / S&P CYRX unavailable / 17.74% |
| 2017-Q11/3 |
LoseCYRX / S&P -27.16% / 6.07% |
WinCYRX / S&P 50.21% / 3.67% |
LoseCYRX / S&P CYRX unavailable / 13.32% |
| 2016-Q42/3 |
WinCYRX / S&P 64.47% / 3.82% |
WinCYRX / S&P 38.98% / 2.09% |
LoseCYRX / S&P CYRX unavailable / 7.05% |
| 2016-Q31/3 |
LoseCYRX / S&P -5.29% / 3.85% |
WinCYRX / S&P 37.02% / 0.20% |
LoseCYRX / S&P CYRX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | CYRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 81.38% | 20.78% |
| Annualized return | 81.38% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | CYRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -75.50% | 83.14% |
| Annualized return | -24.52% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | CYRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 683.92% | 319.30% |
| Annualized return | 22.86% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |